Barclays initiated coverage of Natera with a rating of Overweight and set a new price target of $200.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/23/2025 | $200.00 | Overweight | Barclays |
| 6/3/2024 | $142.00 | Buy | Jefferies |
| 4/8/2024 | $117.00 | Buy | Craig Hallum |
| 2/20/2024 | $68.00 → $85.00 | Strong Buy → Outperform | Raymond James |
| 12/29/2023 | $75.00 → $85.00 | Buy | BTIG Research |
| 12/14/2023 | $70.00 | Buy | Guggenheim |
| 12/13/2023 | $70.00 | Outperform | Wolfe Research |
| 11/13/2023 | $68.00 | Outperform → Strong Buy | Raymond James |
Barclays initiated coverage of Natera with a rating of Overweight and set a new price target of $200.00
Jefferies resumed coverage of Natera with a rating of Buy and set a new price target of $142.00
Craig Hallum resumed coverage of Natera with a rating of Buy and set a new price target of $117.00
8-K - Natera, Inc. (0001604821) (Filer)
8-K - Natera, Inc. (0001604821) (Filer)
144 - Natera, Inc. (0001604821) (Subject)
4 - Natera, Inc. (0001604821) (Issuer)
4 - Natera, Inc. (0001604821) (Issuer)
4 - Natera, Inc. (0001604821) (Issuer)
Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the third quarter ended September 30, 2024. Recent Strategic and Financial Highlights Generated total revenues of $439.8 million in the third quarter of 2024, compared to $268.3 million in the third quarter of 2023, a record increase of 63.9%. Product revenues grew 64.4% over the same period. Generated a gross margin of 61.8% in the third quarter of 2024, compared to a gross margin of 45.1% in the third quarter of 2023. Processed approximately 775,800 tests in the third quarter of 2024, compared to approximately 626,000 tests in the third quarter of 2023, an
Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will release results for its third quarter ended Sept. 30, 2024, after the market closes on Nov. 12, 2024. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET). Earnings Conference Call Information: Event: Natera's Third Quarter 2024 Financial Results Date: Tuesday, Nov. 12, 2024 Time: 1:30 p.m. PT (4:30 p.m. ET) Live Dial-In: 1-888-770-7321 (Domestic) 1-929-201-7107 (International) Conference ID: 7684785 Webc
Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the second quarter ended June 30, 2024. Recent Strategic and Financial Highlights Generated total revenues of $413.4 million in the second quarter of 2024, compared to $261.4 million in the second quarter of 2023, an increase of 58.1%. Product revenues grew 59.3% over the same period. Generated a gross margin of 58.8% in the second quarter of 2024, compared to a gross margin of 45.2% in the second quarter of 2023. Processed approximately 760,300 tests in the second quarter of 2024, compared to approximately 617,200 tests in the second quarter of 2023, an incr
Coverage from one of the largest payors in the country expands access to fetal RhD testing for pregnant patients nationwide Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced a new policy for commercial coverage of its cfDNA Fetal RhD noninvasive prenatal test (Fetal RhD NIPT) from one of the largest payors in the United States. Effective as of Jan. 2025, the policy notes that coverage of fetal RhD testing is available when a pregnancy may be at risk for alloimmunization, when paternal antigen typing is unavailable or heterozygous, and if a patient declines amniocentesis or it is not recommended for the pregnancy. Up to 15 percent
Readout of ~1K patients at ASCO GI 2025 demonstrates that Signatera™ positive patients treated with both chemotherapy and celecoxib had a 40% improvement in overall survival versus chemotherapy alone Additional ASCO GI poster highlights data from the ALTAIR clinical trial, showing significant clinical benefit in patients with stage IV colorectal cancer who were treated with Trifluridine/Tipiracil (FTD/TPI) Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and genetic testing, announced new data from the randomized, Phase III CALGB (Alliance) / SWOG 80702 study. The study will be presented today, Jan. 25, 2025 as a late-breaking oral presentation at the 2025 American Society o
First set of abstracts released include Signatera™ data from BESPOKE CRC, the largest prospective, observational, multicenter MRD study in the U.S. to date, along with the first read-outs in early cancer detection and tissue-free MRD Additional Signatera data will be shared at ASCO GI on Jan. 25, 2025, including a late-breaking oral presentation on the CALGB (Alliance) / SWOG 80702 study Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and genetic testing, today announced that the first set of abstracts have been released from several studies that will be shared at the American Society of Clinical Oncology's Gastrointestinal Cancers Symposium (ASCO GI) taking place Jan. 23 –
SC 13G/A - Natera, Inc. (0001604821) (Subject)
SC 13G/A - Natera, Inc. (0001604821) (Subject)
SC 13G/A - Natera, Inc. (0001604821) (Subject)
Zephyr AI, Inc. ("Zephyr AI"), a company building novel transparent AI to address unmet needs across the full spectrum of precision medicine – from prevention to treatment – to improve patients' lives, today announced the appointment of Eric Lindquist as its new Chief Business Officer. "At Zephyr AI, we have set out to use artificial intelligence and machine learning to bring precision medicine to those suffering from cancer, and our goal is for patients everywhere to be able to find the right treatment, delivered by the right provider, when they need it, enabling them to live healthier and fuller lives," said Grant Verstandig, Co-Founder and Executive Chairman of Zephyr AI. "Eric has bee
Seasoned healthcare executive with extensive leadership experience in health plans, hospital operations, and physician relations Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA testing, today announced that Ruth E. Williams-Brinkley has been appointed to the Company's board of directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230223005436/en/(Photo: Business Wire) Williams-Brinkley has three decades of healthcare industry experience. She currently serves as president of Kaiser Permanente Health Plan of the Mid-Atlantic States (KPMAS), where she oversees the company's care delivery and health plan operations
AUSTIN, Texas, May 24, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA testing, today announced the appointment of Minetta Liu, M.D., as its new chief medical officer (CMO) of oncology. In this role, Dr. Liu will set the direction for the company's clinical and scientific roadmap in oncology, primarily to prove the clinical utility of Signatera™ and incorporate it into standard medical practice across tumor types. "I am very pleased to welcome Dr. Liu to Natera," said Solomon Moshkevich, general manager of oncology at Natera. "As a highly reg